当前位置: 首页 > 详情页

Reversal of P-glycoprotein-mediated multidrug resistance by the novel tetrandrine derivative W6

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China; [3]Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [4]Sichuan Univ, West China Sch Pharm, Dept Chem Med Nat Prod, Chengdu 610064, Peoples R China
出处:
ISSN:

关键词: multidrug resistance W6 P-glycoprotein tetrandrine reversing agents Stephania tetrandra

摘要:
Overexpression of ATP-dependent efflux pump P-glycoprotein (P-gp) is the main cause of multidrug resistance (MDR) and chemotherapy failure in cancer treatment. Inhibition of P-gp-mediated drug efflux is an effective way to overcome cancer drug resistance. The present study investigated the reversal effect of the novel tetrandrine derivative W6 on P-gp-mediated MDR. KBv200, MCF-7/adr and their parental sensitive cell lines KB, MCF-7 were used for reversal study. The intracellular accumulation with P-gp substrates of doxorubicin was determined by flow cytometry. The expression of P-gp and ERK1/2 was investigated by western blot and real-time-PCR (RT-PCR) analysis. ATPase activity of P-gp was performed by P-gp-Glo (TM) assay systems. In comparison with P-gp-negative parental cells, W6 produced a favorable reversal effect in the MDR cells, as determined using the MTT assay. W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. W6 inhibited P-gp expression in KBv200 cells in a time-dependent manner, but it had no effect on MDR1 expression. In addition, W6 significantly decreased the ERK1/2 activation in KBv200 cells. Our results showed that W6 effectively reversed P-gp-mediated MDR by inhibiting the transport function and expression of P-gp, demonstrating the potential clinical utility of W6.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 应用化学 4 区 药物化学 4 区 药学 4 区 植物科学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 应用化学 4 区 药物化学 4 区 药学 4 区 植物科学
JCR分区:
出版当年[2013]版:
Q3 PLANT SCIENCES Q3 CHEMISTRY, APPLIED Q4 PHARMACOLOGY & PHARMACY Q4 CHEMISTRY, MEDICINAL
最新[2023]版:
Q3 PLANT SCIENCES Q3 CHEMISTRY, APPLIED Q4 CHEMISTRY, MEDICINAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China;
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院